Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Megestrol versus medroxyprogesterone for quality of life in menopausal women
IRCT20230930059567N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Nov 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in menopause comparing Megestrol arm with Medroxyprogesterone arm (2 arms). Primary endpoints: Improvement in vasomotor symptoms, Improvement in physical domain and 2 more. Started Nov 2023; status: completed.
02
Drugs
megestrolmedroxyprogesterone acetate
03
Conditions
menopause
Beyond the preview
Go deeper on IRCT20230930059567N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230930059567N1.